Compare ARK Fintech Innovation ETF (ARKF) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Fintech Innovation ETF vs Crispr Therapeutics AG — how do they compare? ARK Fintech Innovation ETF trades at $42.85, while Crispr Therapeutics AG trades at $54.14 (market cap $5.23B). Which is the better fit depends on your goals.
| ARKF | CRSP | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $58.82 | $76.78 |
52-Week Low | $36.14 | $44.34 |
Market Cap | — | $5.23B |
Enterprise Value | — | $3.65B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKF trades at $42.70, down 0.93% today amid a broader fintech and crypto sector consolidation. The ETF's technical outlook is bullish based on moving averages, but oscillators are neutral with an overbought short-term RSI. Recent underperformance includes a 23% decline since July 2025, lagging the S&P 500 by 45 percentage points, with elevated volatility at 33.6%.
Outlook remains cautious due to high valuation multiples and sector headwinds. Risks include stretched P/E of 33x and PEG of 2.0x, signaling potential overvaluation. Investor sentiment is mixed, with a Hold rating reflecting fair valuation concerns amid ongoing consolidation pressures.
CRISPR Therapeutics (CRSP) trades at $53.83, up 0.6% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a Q2 2026 EPS beat with a loss of $0.94 versus an expected $1.19 loss, driven by surging CASGEVY sales. However, financials show deep losses, with a net income margin of -4,101.26% in 2025 and negative operating cash flow, though financing activities provided liquidity.
The outlook is mixed: strong analyst consensus (57.9% buy ratings) and a $82.67 price target reflect optimism around CASGEVY growth and pipeline catalysts, but high valuation (P/S of 466.05) and persistent cash burn pose significant risks. Investment appeal hinges on successful clinical advancements and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Fintech Innovation ETF
ARKF is an actively managed ETF that invests in companies leading the way in fintech innovation. Key themes include mobile payments, digital wallets, blockchain technology, and frictionless funding platforms.
Read more on ARKF →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
